Completed PHASE2 INTERVENTIONAL NCT00398125

Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults

A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK364735 Monotherapy Versus Placebo Over 10 Days in HIV-1 Infected Adults.

Sponsor: GlaxoSmithKline

Conditions HIV-1 Infection Infection, Human Immunodeficiency Virus

Interventions GSK364735

Updated 6 times since 2017 Last updated: Jul 26, 2012 Started: Nov 30, 2006 Completion: Apr 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on HIV-1 Infection and Infection, Human Immunodeficiency Virus, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 6 data snapshots since 2006. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Birmingham, United States , Dallas, United States , Denver, United States , Fort Lauderdale, United States , Hollywood, United States , Los Angeles, United States , Newark, United States , Orlando, United States , San Diego, United States and 2 more locations